American International Group Inc. Raises Position in Fluidigm Corporation (FLDM)
American International Group Inc. raised its position in shares of Fluidigm Corporation (NASDAQ:FLDM) by 7.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,907 shares of the medical research company’s stock after buying an additional 1,187 shares during the period. American International Group Inc. owned approximately 0.06% of Fluidigm Corporation worth $102,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. AQR Capital Management LLC acquired a new position in shares of Fluidigm Corporation during the fourth quarter worth $119,000. Metropolitan Life Insurance Co. NY increased its position in shares of Fluidigm Corporation by 3.1% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,789 shares of the medical research company’s stock worth $151,000 after buying an additional 632 shares in the last quarter. Stoneridge Investment Partners LLC increased its position in shares of Fluidigm Corporation by 4.2% in the first quarter. Stoneridge Investment Partners LLC now owns 25,293 shares of the medical research company’s stock worth $144,000 after buying an additional 1,013 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Fluidigm Corporation by 15.0% in the first quarter. Wells Fargo & Company MN now owns 25,521 shares of the medical research company’s stock worth $146,000 after buying an additional 3,327 shares in the last quarter. Finally, Falcon Point Capital LLC increased its position in shares of Fluidigm Corporation by 3.1% in the first quarter. Falcon Point Capital LLC now owns 40,661 shares of the medical research company’s stock worth $231,000 after buying an additional 1,238 shares in the last quarter. Institutional investors own 91.66% of the company’s stock.
Shares of Fluidigm Corporation (FLDM) traded down 0.2988% during trading on Friday, hitting $3.3699. The stock had a trading volume of 17,895 shares. Fluidigm Corporation has a 1-year low of $2.52 and a 1-year high of $9.65. The company’s market capitalization is $99.12 million. The firm has a 50 day moving average of $3.76 and a 200 day moving average of $4.97.
Fluidigm Corporation (NASDAQ:FLDM) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.02. The firm had revenue of $23.90 million for the quarter, compared to analyst estimates of $23.50 million. Fluidigm Corporation had a negative return on equity of 121.04% and a negative net margin of 74.05%. The business’s quarterly revenue was down 15.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.63) EPS. Analysts expect that Fluidigm Corporation will post ($2.19) EPS for the current fiscal year.
A number of equities analysts have recently weighed in on the company. ValuEngine downgraded Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Zacks Investment Research downgraded Fluidigm Corporation from a “hold” rating to a “sell” rating in a report on Friday, May 12th.
In other Fluidigm Corporation news, Director Evan/ Fa Jones sold 10,900 shares of the business’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $4.54, for a total transaction of $49,486.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Steven Mcphail purchased 20,000 shares of the stock in a transaction on Tuesday, August 8th. The shares were bought at an average cost of $3.00 per share, for a total transaction of $60,000.00. Following the transaction, the insider now directly owns 27,842 shares in the company, valued at $83,526. The disclosure for this purchase can be found here. Insiders have acquired a total of 100,895 shares of company stock worth $279,129 in the last ninety days. Insiders own 4.70% of the company’s stock.
Fluidigm Corporation Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Stock Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related stocks with our FREE daily email newsletter.